-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
United States Pharmaceutical Isolators Market Analysis Report 2021 - ResearchAndMarkets.com
United States Pharmaceutical Isolators Market Analysis Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "U.S. Pharmaceutical Isolators Market Size, Share & Trends Analysis Report By Type (Open Isolator, Close Isolator), By Pressure (Positive Pressure, Negative Pressure), And Segment Forecasts, 2020 - 2028" report has been added to ResearchAndMarkets.com's offering.
The U.S. pharmaceutical isolators market size is expected to reach USD 205.2 million by 2028, registering a CAGR of 5.8% from 2020 to 2028
The rapid growth of the pharmaceutical industry in the U.S. and advancements in technologies used in the industry are anticipated to have a positive impact on market growth.
The growth of the industry in the U.S. is primarily driven by continuous progress in the field of medicines and bioscience. The rising demand for aseptically processed parenteral medicines, along with increased investments in the industry, is anticipated to drive the market in the U.S.
Pharmaceutical isolators are seeing fast-paced technological advancements in aseptic processing in terms of incorporation of robotics and automation solutions and industry 4.0. By integrating robotics within gloveless pharmaceutical isolators, the risk of microbe contamination, as well as particle contamination caused by human intervention is reduced.
The industry is moving toward energy efficiency and sustainability. Pharmaceutical isolators offer higher energy efficiency as compared to the Restricted Access Barrier System (RABS). Energy saving in pharmaceutical isolators can be up to 65% as compared to 30% offered by RABS which is likely to positively improve their demand.
U.S. Pharmaceutical Isolators Market Report Highlights
- The closed isolators segment is expected to witness a CAGR of 5.5% from 2020 to 2028 owing to the ability to operate without personnel access to the critical zone, making them suitable for application in the preparation of toxic materials
- The positive pressure segment accounted for 53.9% of the overall revenue share in 2020, owing to its demand in sterile processes when the process is of particular significance and keeping any contaminants out of the isolator is a priority
- Companies are collaborating with educational institutions along with their in-house R&D facilities for developing processes and technologies that offer a sustainable advantage in the future
- In February 2021, Comecer S.p.A partnered with Illuminate Manufacturing Intelligence, to integrate Illuminate, a pharmaceutical production solution based on industry 4.0, to get real-time updates of their manufacturing equipment
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Pharmaceutical Isolators Market Variables, Trends, & Scope
Chapter 4. U.S. Pharmaceutical Isolators Market: Type Estimates & Trend Analysis
Chapter 5. U.S. Pharmaceutical Isolators Market: Pressure Estimates & Trend Analysis
Chapter 6. U.S. Pharmaceutical Isolators Market: Competitive Analysis
Chapter 7. Company Profiles
- Comecer S.P.A.
- Laf Technologies
- Iso Tech Design
- Nuaire
- Getinge Ab
- Skan Ag
- M. Braun Inertgas-Systeme Gmbh
- Azbil Telstar, S.L.U.
- Syntegon Technologies Gmbh
- IMA Group
For more information about this report visit
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
DUBLIN--(BUSINESS WIRE)--The "U.S. Pharmaceutical Isolators Market Size, Share & Trends Analysis Report By Type (Open Isolator, Close Isolator), By Pressure (Positive Pressure, Negative Pressure), And Segment Forecasts, 2020 - 2028" report has been added to ResearchAndMarkets.com's offering.
都柏林--(美国商业新闻网)--《2020-2028年美国药品隔离器市场规模、份额和趋势分析报告》(按类型(Open Isolator、Close Isolator)、按压力(正压、负压)和细分市场预测)新增报告Research andMarkets.com的献祭。
The U.S. pharmaceutical isolators market size is expected to reach USD 205.2 million by 2028, registering a CAGR of 5.8% from 2020 to 2028
预计到2028年,美国药物隔离剂的市场规模将达到2.052亿美元,2020-2028年的复合年增长率为5.8%
The rapid growth of the pharmaceutical industry in the U.S. and advancements in technologies used in the industry are anticipated to have a positive impact on market growth.
美国制药业的快速增长和该行业所用技术的进步预计将对市场增长产生积极影响。
The growth of the industry in the U.S. is primarily driven by continuous progress in the field of medicines and bioscience. The rising demand for aseptically processed parenteral medicines, along with increased investments in the industry, is anticipated to drive the market in the U.S.
该行业在美国的增长主要是由药物和生物科学领域的持续进步推动的。对无菌处理的非肠道药物的需求不断上升,加上对该行业投资的增加,预计将推动美国的市场。
Pharmaceutical isolators are seeing fast-paced technological advancements in aseptic processing in terms of incorporation of robotics and automation solutions and industry 4.0. By integrating robotics within gloveless pharmaceutical isolators, the risk of microbe contamination, as well as particle contamination caused by human intervention is reduced.
在机器人和自动化解决方案以及工业4.0的结合方面,药物隔离器在无菌处理方面看到了快速的技术进步。通过将机器人技术集成到无手套药物隔离器中,降低了由人为干预引起的微生物污染和颗粒污染的风险。
The industry is moving toward energy efficiency and sustainability. Pharmaceutical isolators offer higher energy efficiency as compared to the Restricted Access Barrier System (RABS). Energy saving in pharmaceutical isolators can be up to 65% as compared to 30% offered by RABS which is likely to positively improve their demand.
该行业正在朝着节能和可持续发展方向发展。与受限访问屏障系统(RABS)相比,药物隔离器具有更高的能效。与RABS提供的30%相比,药物隔离器的节能可高达65%,这可能会积极改善他们的需求。
U.S. Pharmaceutical Isolators Market Report Highlights
美国药品隔离器市场报告亮点
- The closed isolators segment is expected to witness a CAGR of 5.5% from 2020 to 2028 owing to the ability to operate without personnel access to the critical zone, making them suitable for application in the preparation of toxic materials
- The positive pressure segment accounted for 53.9% of the overall revenue share in 2020, owing to its demand in sterile processes when the process is of particular significance and keeping any contaminants out of the isolator is a priority
- Companies are collaborating with educational institutions along with their in-house R&D facilities for developing processes and technologies that offer a sustainable advantage in the future
- In February 2021, Comecer S.p.A partnered with Illuminate Manufacturing Intelligence, to integrate Illuminate, a pharmaceutical production solution based on industry 4.0, to get real-time updates of their manufacturing equipment
- 从2020年到2028年,闭式隔离器段的复合年均增长率预计将达到5.5%,因为它能够在没有人员进入临界区的情况下运行,使其适用于有毒材料的制备
- 2020年,正压部分占总收入的53.9%,这是因为它在无菌过程中的需求,因为该过程具有特别重要的意义,而且优先考虑将任何污染物排除在隔离器之外
- 公司正在与教育机构及其内部研发机构合作,以开发能够在未来提供可持续优势的流程和技术。
- 2021年2月,Comecer S.p.A与Lightate Manufacturing Intelligence合作,集成了基于工业4.0的制药生产解决方案Lightate,以获得其制造设备的实时更新
Key Topics Covered:
涵盖的主要主题:
Chapter 1. Methodology and Scope
第一章方法和范围
Chapter 2. Executive Summary
第2章.执行摘要
Chapter 3. U.S. Pharmaceutical Isolators Market Variables, Trends, & Scope
第三章美国药物隔离器市场变量、趋势和范围
Chapter 4. U.S. Pharmaceutical Isolators Market: Type Estimates & Trend Analysis
第四章美国药物隔离器市场:类型估计与趋势分析
Chapter 5. U.S. Pharmaceutical Isolators Market: Pressure Estimates & Trend Analysis
第五章美国药物隔离器市场:压力评估与趋势分析
Chapter 6. U.S. Pharmaceutical Isolators Market: Competitive Analysis
第六章美国药物隔离器市场:竞争分析
Chapter 7. Company Profiles
第七章.公司概况
- Comecer S.P.A.
- Laf Technologies
- Iso Tech Design
- Nuaire
- Getinge Ab
- Skan Ag
- M. Braun Inertgas-Systeme Gmbh
- Azbil Telstar, S.L.U.
- Syntegon Technologies Gmbh
- IMA Group
- Comecer S.P.A.
- LAF技术
- ISO技术设计
- 努伊尔
- 格廷格抗体
- Skan Ag
- M.Braun Inertgas-Systeme GmbH
- 拉斯维加斯大学阿兹比勒·泰尔斯塔尔(Azbil Telstar)
- Syntegon Technologies GmbH
- IMA集团
For more information about this report visit
有关本报告的更多信息,请访问
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
ResearchAndMarkets.com劳拉·伍德(Laura Wood),高级新闻经理邮箱:press@researchandmarket s.com东部夏令时办公时间请拨打1-917-300-0470美国/加拿大免费电话:1-800-526-8630对于格林尼治标准时间办公时间,请致电+353-1-416-8900
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧